Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEONEL REYES JR.

Allopathic & Osteopathic Physicians Family Medicine

NPI
1841302049
CMS profile
220107
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$565.96

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $559.34 16
Education $6.62 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ITI, Inc. $322.57 14
Amgen Inc. $121.82 1
Abbott Laboratories $86.49 1
Galderma Laboratories, L.P. $20.29 1
Lilly USA, LLC $14.79 1

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEONEL REYES JR.

NPI 1841302049 · CMS profile ID 220107

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841302049?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841302049?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841302049?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1841302049?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $565.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $86.4912/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908738319 CMS
ITI, Inc. $20.0012/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711167 CMS
ITI, Inc. $21.9411/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711165 CMS
Lilly USA, LLC $14.7911/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918154035 CMS
ITI, Inc. $124.9810/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711163 CMS
ITI, Inc. $19.4510/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711161 CMS
Galderma Laboratories, L.P. $20.2910/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952292351 CMS
ITI, Inc. $21.6209/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711159 CMS
ITI, Inc. $17.5708/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711157 CMS
ITI, Inc. $14.2308/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711155 CMS
ITI, Inc. $18.9506/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711153 CMS
Amgen Inc. $121.8205/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939884963 CMS
ITI, Inc. $19.2005/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711151 CMS
ITI, Inc. $15.8704/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711147 CMS
ITI, Inc. $2.5204/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711149 CMS
ITI, Inc. $19.6203/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711145 CMS
ITI, Inc. $3.3102/07/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711143 CMS
ITI, Inc. $3.3101/04/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945711141 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $382.31 5
PY2020 $516.96 25
PY2021 $254.93 16
PY2022 $565.96 18
PY2023 $1,847.77 31
PY2024 $2,875.29 31
PY2025 $3,306.12 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $755,211.02 111
PY2024 Recipient $1,229.18 7
PY2024 Principal investigator $859,657.92 144
PY2023 Recipient $884.12 7
PY2023 Principal investigator $2,118,069.52 144
PY2022 Recipient $3,289.97 13
PY2022 Principal investigator $555,785.63 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

111 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $16,000.00 12/31/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228805462
Principal investigator 1 PFIZER INC. $74.30 12/26/2025 Non-covered Recipient Entity
Sun Research Institute
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228804249
Principal investigator 1 PFIZER INC. $58.50 12/26/2025 Non-covered Recipient Entity
Sun Research Institute
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228805473
Principal investigator 1 Ardelyx, Inc. $4,114.00 12/16/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838913
Principal investigator 1 Ardelyx, Inc. $4,000.00 12/16/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838917
Principal investigator 1 Ardelyx, Inc. $2,719.00 12/16/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838922
Principal investigator 1 ABBVIE INC. $2,750.00 12/09/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202529702
Principal investigator 1 ABBVIE INC. $3,333.00 12/09/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202529712
Principal investigator 1 ABBVIE INC. $2,200.00 12/09/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202529714
Principal investigator 1 ABBVIE INC. $7,635.20 12/04/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527340
Principal investigator 1 ABBVIE INC. $3,676.05 12/04/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202527342
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,048.35 12/01/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288879
Principal investigator 1 Ardelyx, Inc. $4,000.00 11/25/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838836
Principal investigator 1 Ardelyx, Inc. $2,561.00 11/25/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838840
Principal investigator 1 Ardelyx, Inc. $2,527.70 11/25/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838843
Principal investigator 1 Ardelyx, Inc. $200.00 11/25/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838848
Principal investigator 1 ABBVIE INC. $444.00 11/20/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524804
Principal investigator 1 ABBVIE INC. $444.00 11/19/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524624
Principal investigator 1 Janssen Research & Development, LLC $2,136.00 11/19/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284612
Principal investigator 1 ABBVIE INC. $5,000.00 11/13/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524057
Principal investigator 1 PFIZER INC. $148.60 11/13/2025 Non-covered Recipient Entity
Sun Research Institute
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228805468
Principal investigator 1 PFIZER INC. $117.00 11/13/2025 Non-covered Recipient Entity
Sun Research Institute
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228805548
Principal investigator 1 ABBVIE INC. $3,720.00 11/12/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202523819
Principal investigator 1 ABBVIE INC. $4,400.00 11/12/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202523821
Principal investigator 1 Janssen Research & Development, LLC $2,356.00 11/07/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284464
Principal investigator 1 ABBVIE INC. $7,011.90 11/05/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202521537
Principal investigator 1 Janssen Research & Development, LLC $1,705.00 11/05/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175285932
Principal investigator 1 ABBVIE INC. $32,025.76 11/04/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520201
Principal investigator 1 Ardelyx, Inc. $5,347.50 11/04/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838791
Principal investigator 1 Janssen Research & Development, LLC $5,416.00 11/03/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175285554
Principal investigator 1 PFIZER INC. $7,920.00 10/25/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228824683
Principal investigator 1 PFIZER INC. $1,279.80 10/24/2025 Non-covered Recipient Entity
Sun Research Institute
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228810490
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,101.78 10/17/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223287085
Principal investigator 1 PFIZER INC. $5,040.00 10/15/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228824677
Principal investigator 1 ABBVIE INC. $7,398.40 10/09/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202514239
Principal investigator 1 Novartis Pharmaceuticals Corporation $163,142.02 10/09/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190301623
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 10/03/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223286363
Principal investigator 1 Ardelyx, Inc. $8,545.50 10/02/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838627
Principal investigator 1 Ardelyx, Inc. $5,727.00 10/02/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838631
Principal investigator 1 Ardelyx, Inc. $1,600.00 10/02/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838635
Principal investigator 1 ABBVIE INC. $8,665.65 10/01/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202512924
Principal investigator 1 Janssen Research & Development, LLC $3,427.00 09/19/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284262
Principal investigator 1 ABBVIE INC. $14,368.00 09/18/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202511522
Principal investigator 1 ABBVIE INC. $15,543.20 09/03/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202507855
Principal investigator 1 ABBVIE INC. $3,354.75 09/02/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202506949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,725.00 09/02/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223284771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,300.00 09/02/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223284773
Principal investigator 1 ABBVIE INC. $3,354.75 08/27/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202506001
Principal investigator 1 ABBVIE INC. $1,552.00 08/26/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202505821
Principal investigator 1 ABBVIE INC. $1,550.00 08/26/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202505835
Principal investigator 1 ABBVIE INC. $348.00 08/25/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202505683
Principal investigator 1 Janssen Research & Development, LLC $1,409.00 08/25/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284426
Principal investigator 1 Janssen Research & Development, LLC $880.00 08/21/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175402264
Principal investigator 1 Ardelyx, Inc. $5,751.00 08/18/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838554
Principal investigator 1 PFIZER INC. $1,750.68 08/14/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228843498
Principal investigator 1 Janssen Research & Development, LLC $1,600.00 08/06/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175285178
Principal investigator 1 ABBVIE INC. $7,168.96 08/05/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202501706
Principal investigator 1 ABBVIE INC. $2,600.00 08/05/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501786
Principal investigator 1 PFIZER INC. $257.45 07/25/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228848163
Principal investigator 1 Janssen Research & Development, LLC $3,148.00 07/23/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284540
Principal investigator 1 Ardelyx, Inc. $6,573.27 07/22/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838488
Principal investigator 1 Ardelyx, Inc. $185.23 07/22/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838492
Principal investigator 1 PFIZER INC. $7,518.49 07/16/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228848155
Principal investigator 1 ABBVIE INC. $3,354.75 07/08/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202497148
Principal investigator 1 Ardelyx, Inc. $1,659.00 07/07/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838466
Principal investigator 1 ABBVIE INC. $3,000.00 07/02/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494805
Principal investigator 1 ABBVIE INC. $1,637.12 07/02/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494807
Principal investigator 1 Janssen Research & Development, LLC $1,668.00 06/20/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175285844
Principal investigator 1 PFIZER INC. $10,350.44 06/14/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228851922
Principal investigator 1 ABBVIE INC. $10,548.80 06/05/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202490507
Principal investigator 1 Ardelyx, Inc. $3,694.77 05/28/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838382
Principal investigator 1 Ardelyx, Inc. $931.63 05/28/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838386
Principal investigator 1 Ardelyx, Inc. $898.60 05/28/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838390
Principal investigator 1 PFIZER INC. $1,029.80 05/28/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228857578
Principal investigator 1 ABBVIE INC. $8,665.65 05/27/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202486215
Principal investigator 1 Janssen Research & Development, LLC $1,178.00 05/21/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175285792
Principal investigator 1 Ardelyx, Inc. $1,145.40 05/20/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838375
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,899.22 05/09/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185540523
Principal investigator 1 ABBVIE INC. $3,592.00 05/08/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202484391
Principal investigator 1 ABBVIE INC. $5,373.60 05/07/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202483121
Principal investigator 1 ABBVIE INC. $1,390.72 05/06/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481647
Principal investigator 1 PFIZER INC. $514.90 05/06/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228857562
Principal investigator 1 PFIZER INC. $4,376.65 05/01/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228857585
Principal investigator 1 ABBVIE INC. $2,200.00 04/30/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202480639
Principal investigator 1 Ardelyx, Inc. $2,094.50 04/29/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838298
Principal investigator 1 Ardelyx, Inc. $405.50 04/29/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838303
Principal investigator 1 ABBVIE INC. $2,310.00 04/23/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202478711
Principal investigator 1 Janssen Research & Development, LLC $4,078.00 04/23/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284972
Principal investigator 1 ABBVIE INC. $2,200.00 04/17/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202477732
Principal investigator 1 Ardelyx, Inc. $2,500.00 04/15/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1247838261
Principal investigator 1 PFIZER INC. $3,346.85 04/08/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228858615
Principal investigator 1 ABBVIE INC. $19,003.84 04/03/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473674
Principal investigator 1 ABBVIE INC. $1,390.72 04/03/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202473993
Principal investigator 1 Ardelyx, Inc. $2,109.00 04/02/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838217
Principal investigator 1 AstraZeneca UK Limited $52,549.02 04/01/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185540525
Principal investigator 1 Ardelyx, Inc. $3,541.50 03/24/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838210
Principal investigator 1 PFIZER INC. $5,311.07 03/22/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228861864
Principal investigator 1 Janssen Research & Development, LLC $6,545.00 03/21/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175285521
Principal investigator 1 Janssen Research & Development, LLC $1,086.00 03/17/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175402252
Principal investigator 1 ABBVIE INC. $2,121.60 03/07/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202459257
Principal investigator 1 ABBVIE INC. $10,360.80 03/07/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202462003
Principal investigator 1 Janssen Research & Development, LLC $362.00 03/03/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175402258
Principal investigator 1 Janssen Research & Development, LLC $3,167.00 02/19/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284184
Principal investigator 1 Ardelyx, Inc. $5,817.06 02/10/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838113
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,209.00 02/07/2025 Non-covered Recipient Entity
Sun Research Institute
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235993431
Principal investigator 1 ABBVIE INC. $11,631.36 02/06/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202448700
Principal investigator 1 PFIZER INC. $52,528.26 01/30/2025 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228863406
Principal investigator 1 Janssen Research & Development, LLC $264.00 01/22/2025 Non-covered Recipient Entity
Sun Rsrch Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175284369
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,688.10 01/03/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185540521
Principal investigator 1 ABBVIE INC. $80.00 01/02/2025 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202435619
Principal investigator 1 Ardelyx, Inc. $1,448.00 01/02/2025 Non-covered Recipient Entity
VALENCIA MEDICAL AND RESEARCH CENTER
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838012